TOP TEN perturbations for 1419_g_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1419_g_at
Selected probe(set): 210037_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1419_g_at (210037_s_at) across 6537 perturbations tested by GENEVESTIGATOR:

ulcerative colitis study 4 (inflamed) / normal colon mucosa tissue (IBS)

Relative Expression (log2-ratio):3.326582
Number of Samples:8 / 17
Experimental ulcerative colitis study 4 (inflamed)
Mucosa biopsy samples derived from the descending colon from areas with macroscopic and microscopic signs of inflammation derived from patients with ulcerative colitis.
Control normal colon mucosa tissue (IBS)
Mucosa biopsies derived from the descending colon from patients with the diagnosis of irritable bowel syndrome due to normal test results in different investigations including colonoscopy.

Crohn's disease study 10 / colorectal cancer study 13 (hypp. pol.)

Relative Expression (log2-ratio):3.0840054
Number of Samples:4 / 11
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (hypp. pol.)
Colon biopsies derived from patients with hyperplastic polyps.

ulcerative colitis study 5 (baseline; responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):2.988823
Number of Samples:8 / 6
Experimental ulcerative colitis study 5 (baseline; responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):2.9634228
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

ulcerative colitis study 11 / normal colon tissue

Relative Expression (log2-ratio):2.834549
Number of Samples:3 / 3
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control normal colon tissue
Colon biopsies derived from healthy controls.

ulcerative colitis study 11 / colorectal cancer study 13 (hypp. pol.)

Relative Expression (log2-ratio):2.800974
Number of Samples:3 / 11
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (hypp. pol.)
Colon biopsies derived from patients with hyperplastic polyps.

ulcerative colitis study 29 (infliximab; 5mg/kg; responder; 30wk) / ulcerative colitis study 29 (infliximab; 5mg/kg; non-responder; 30wk)

Relative Expression (log2-ratio):-2.7245464
Number of Samples:6 / 3
Experimental ulcerative colitis study 29 (infliximab; 5mg/kg; responder; 30wk)
Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 5 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code:
Control ulcerative colitis study 29 (infliximab; 5mg/kg; non-responder; 30wk)
Colonic mucosal biopsies from ulcerative colitis patients who are non-responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 5 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code:

Crohn's disease study 10 / colorectal cancer study 13 (crc)

Relative Expression (log2-ratio):2.6617203
Number of Samples:4 / 7
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (crc)
Colon biopsies derived from patients with colorectal carcinoma.

ulcerative colitis study 12 / normal colorectal tissue

Relative Expression (log2-ratio):2.6598854
Number of Samples:7 / 8
Experimental ulcerative colitis study 12
Tissue biopsy samples derived from patients diagnosed with severe active ulcerative colitis localized in different colorectal regions .
Control normal colorectal tissue
Normal tissue biopsies derived from different colorectal regions of healthy controls.

ulcerative colitis study 5 (infliximab; 5mg/kg; responder) / ulcerative colitis study 5 (baseline; responder)

Relative Expression (log2-ratio):-2.6275215
Number of Samples:7 / 8
Experimental ulcerative colitis study 5 (infliximab; 5mg/kg; responder)
Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment, taken after the first intravenous infusion of 5 mg infliximab per kg body weight. Biopsies were taken 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if patients received a loading dose of infliximab at weeks 0, 2 and 6. The response to infliximab was assessed at 4 to 6 weeks after the first infliximab treatment, respectively. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. ATC code:
Control ulcerative colitis study 5 (baseline; responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.